Last reviewed · How we verify

NCT06585800

Exploring the Landscape of Somatic Mutations in Human Tissue

ENROLLING BY INVITATION Last updated 19 September 2024
What this trial tests

trial testing sample collection in Somatic Mutation in 1,800 participants. Enrolling by invitation.

Timeline
1 March 2019
Primary endpoint
31 January 2026
31 January 2026

Quick facts

Lead sponsorThe Wellcome Sanger Institute
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment1,800
Start date1 March 2019
Primary completion31 January 2026
Estimated completion31 January 2026
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

The Wellcome Sanger Institute

Who can join

18 and older, any sex, with Somatic Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Every cell in the human body contains a blueprint of the body called the genome. Throughout life, the genome can become damaged resulting in errors (mutations) that can change the way cells behave and may result in diseases such as cancer. Examining the mutations found the genome of both normal (non-cancerous) and diseased cells can give a valuable insight into the very earliest stages of cancer development. Comparing the number and type of mutations in different normal tissues is revealing new insights, helping us to better understand more about why cancer develops.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of sample collection

Trials testing the same drug.

Other recruiting trials for Somatic Mutation

Currently open trials in the same condition.

Other The Wellcome Sanger Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing